Titlebook: DNA Topoisomerases and Cancer; Yves Pommier Book 2012 Springer Science+Business Media, LLC 2012 Tyrosyl-DNA-Phosphodiesterase.Ubiquitin.an

優(yōu)雅

Tyrosyl-DNA-Phosphodiesterase,f 3′-phosphodiester linkages, potentially implicating Tdp1 in other DNA repair pathways. In this chapter we summarize the recent advances in research concerning Tdp1, alternative repair pathways for repairing Top1-induced DNA damage, and the rational for targeting Tdp1 as a potential anticancer ther

GREG

秘方藥

財(cái)主

abduction

Joyce Mahon,Brett A. Becker,Brian Mac NameeTopo III, and Topo IV) and eukaryotic cells (Topo IB, Topo II, Topo III). Later on, new families and subfamilies of DNA topoisomerases were discovered in Archaea, the third domain of life (reverse gyrase, Topo V, Topo VI), challenging the prokaryote/eukaryote dichotomy. DNA topoisomerases are now cl

蹣跚

六邊形

B. Samirana Acharya,K. Ramasubramanianthecins include edotecarin, an indolocarbazole that results in DNA C/T-G cleavage compared with T-G/A for camptothecins. Indenoisoquinolines identified as Top1 inhibitors by the “NCI 60-cell line COMPARE” analysis are in clinical development. Dibenzonaphthyridinone Top1 inhibitors have undergone ext

aesthetic

Alexei Gvishiani,Jacques Octave Duboisthat may have clinical promise. Although currently used Top2 targeting drugs act by generating enzyme-mediated DNA damage, catalytic inhibition remains a tantalizing possibility. Since current results suggest that topoisomerase IIβ, one of the two mammalian isoforms of topoisomerase II, is important

Offensive

Alexei Gvishiani,Jacques Octave Duboisalso provides a glimpse at other Top1 inhibitors under development. Advances in our understanding of Top1 action covered elsewhere in this volume, and reasons for selectivity and resistance will undoubtedly extend the clinical applications of these drugs.

征兵